Skip to main content

Table 1 Patient and procedure characteristics and study drug administration

From: A randomized, double-blind, placebo controlled safety, tolerability, and pharmacokinetic dose escalation study of a gentamicin vancomycin gel in patients undergoing colorectal surgery

Characteristic

Placebo

DFA-02 ≤10 mL

DFA-02 >10 mL

(n = 6)

(n = 16)

(n = 8)

Age, years

56.5 (45.1,60.6)

70.9 (63.2, 76.3)

46.9 (41.4, 61.2)

Gender, % male

2 (33.3 %)

6 (37.5 %)

4 (50 %)

Race, % white

5 (83.3 %)

14 (87.5 %)

7 (87.5 %)

Weight, kg

74.7 (72.3,76.4)

90.9 (72.3,97.1)

81.8 (73.3, 97.5)

Height, cm

164.3 (157.5, 175.2)

167.6 (158.7, 175.3)

171.4 (165.1, 180.4)

Body mass index (kg/m2)

28.2 (27.0, 29.9)

29.1 (27.8, 33.9)

28.2 (25.7, 30.6)

Preoperative serum creatinine (mg/dL)

0.7 (0.7, 0.9)

0.9 (0.8, 1.3)

0.9 (0.8, 1.0)

Duration of surgical procedure (h)

2.8 (1.4, 4.6)

2.0 (1.1, 2.3)

3.0 (2.4, 5.6)

Length of incision (cm)

11.3 (8.0, 26.0)

8.2 (7.8, 10.0)

8.5 (7.8, 10.5)

Depth of incision at midpoint (cm)

2.2 (1.5, 3.0)

2.5 (1.5, 3.3)

2.5 (2.0, 3.0)

Wound area (cm2)

45.7 (11.1, 79.7)

22.3 (12.1, 30.0)

22.8 (18.0, 32.3)

Study drug volume inserted into wound (mL)

19.0 (10.0, 20.0)

10.0 (10.0, 20.0)

25.0 (20.0, 30.0)

Overflow study drug collected (mL)

4.5 (3.0, 7.0)

5.0 (1.5, 12.5)

12.0 (6.0, 15.0)

Volume of study drug retained in wound (mL)

9.5 (5.0, 17.0)

5.0 (4.5, 9.8)

15.0 (12.5, 15.5)

Volume of study drug per wound area (mL/cm2)

0.2 (0.2, 0.5)

0.3 (0.2, 0.4)

0.6 (0.5, 0.7)

  1. As appropriate data shown as percentage or median (25th, 75th percentiles)